Is Galectin Therapeutics Inc. (GALT) a Buy, Sell, or Hold?
Galectin Therapeutics Inc.
NASDAQ:GALT
$4.9154 USD
-$0.42 (-7.95%)
- Volume
- 406.61K
- Average Volume
- 609.99K
- Market Capitalization
- $323.71M
- P/E Ratio
- -12.08
- Dividend Yield
- 0.00%
- Price Target
- $11.00
- Year High
- $7.13
- Year Low
- $2.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.15
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Joel Lewis |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | GALT |
| CUSIP | 363225202 |
| CIK | 0001133416 |
| Web | https://galectintherapeutics.com |
| Phone | 678 620 3186 |
| Currency | USD |
| Employees | 9 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -1.04 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.15 |
| Quick Ratio | 2.15 |
| Cash Ratio | 1.93 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.30 |
| Price / Cash Flow | -16.14 |
| Price / Book | -2.48 |
Price Target and Rating
| Average Stock Price Forecast | $11.00 |
| High Stock Price Forecast | $11.00 |
| Low Stock Price Forecast | $11.00 |
| Forecast Upside/Downside | -55.31% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 11 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.48 |
| Trailing P/E Ratio | -12.08 |
| PEG Ratio | -0.19 |
| P/E Growth | -0.19 |
| Net Income | $-30.84M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | 21.05% |
| Return on Assets | -166.58% |
Financials Score
| AltmanZ Score | -40.70 |
| Piotroski Score | 2.00 |
| Working Capital | 8.38M |
| Total Assets | 15.76M |
| Ebit | -18.68M |
| Market Cap | 351.68M |
| Total Liabilities | 146M |
Poll Results
About Galectin Therapeutics Inc. (NASDAQ:GALT) Stock
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring addit ... ional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside
2026-06-24 14:02:08
Galectin Therapeutics remains a buy as recent FDA alignment de-risks belapectin's Phase 3 path and clarifies regulatory endpoints. The FDA's endorsement of a single, well-controlled Phase 3 trial with a composite clinical outcome endpoint reduces uncertainty and shortens timelines. GALT's valuation reflects skepticism about execution, financing risk, and commercial viability, but successful Phase 3 results could trigger a significant re-rating.
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
2026-06-24 11:06:03
Galectin stock rises following FDA alignment on key elements of belapectin's phase III MASH cirrhosis program, clarifying a potential path toward full approval.
2026-06-23 08:00:00
NORCROSS, Ga., June 23, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies for patients with advanced liver disease, today announced positive feedback from its recent in person Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of belapectin for the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension.
2026-05-27 08:00:00
NORCROSS, Ga., May 27, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced the oral and poster presentations of new analyses from its global NAVIGATE trial of belapectin at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27–30, 2026, in Barcelona, Spain.
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
2026-05-15 08:00:00
NORCROSS, Ga., May 15, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2026.
2026-05-11 08:00:00
NORCROSS, Ga., May 11, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced the publication of results from its NAVIGATE Phase 2b clinical trial evaluating belapectin in patients with MASH cirrhosis and portal hypertension in AASLD flagship journal Hepatology.
Galectin Therapeutics, Inc. Investigated by the Portnoy Law Firm
2026-04-27 09:00:00
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Galectin Therapeutics, Inc., (“Galectin" or the "Company") (NASDAQ: GALT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact attorney Lesley F.
Frequently Asked Questions
-
What is the current Galectin Therapeutics Inc. (GALT) stock price?
-
Galectin Therapeutics Inc.(NASDAQ:GALT) stock price is $4.9154 in the last trading session. During the trading session, GALT stock reached the peak price of $7.13 while $2.03 was the lowest point it dropped to. The percentage change in GALT stock occurred in the recent session was --7.95% while the dollar amount for the price change in GALT stock was -$-0.42.
-
GALT's industry and sector of operation?
-
The NASDAQ listed GALT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GALT?
-
Jack W. Callicutt | Chief Financial Officer, Treasurer & Corporate Secretary
Joel Lewis | President & CEO
Jim Wilkins | Head of CMC & Pharmaceutical Development
Beth Knowles | Executive Assistant & Officer Manager
Robert Tritt | General Counsel -
How many employees does GALT have?
-
Number of GALT employees currently stands at 9. GALT operates from 4960 Peachtree Industrial Boulevard, Norcross, GA 30071, US.
-
Link for GALT official website?
-
Official Website of GALT is: https://galectintherapeutics.com
-
How do I contact GALT?
-
GALT could be contacted at phone #678 620 3186 and can also be accessed through its website. GALT operates from 4960 Peachtree Industrial Boulevard, Norcross, GA 30071, US.
-
How many shares of GALT are traded daily?
-
The average number of GALT shares traded daily for last 3 months was 609.99K.
-
What is the market cap of GALT currently?
-
The market value of GALT currently stands at $323.71M with its latest stock price at $4.9154